Pre-operative chemoradiation followed by post-operative adjuvant therapy with tetrathiomolybdate, a novel copper chelator, for patients with resectable esophageal cancer

详细信息    查看全文

• 作者：Bryan J. Schneider (1)
  Julia Shin-Jung Lee (2) (9)
  James A. Hayman (3)
  Andrew C. Chang (4)
  Mark B. Orringer (4)
  Allan Pickens (5)
  Charlie C. Pan (6)
  Sofia D. Merajver (7) (8)
  Susan G. Urba (10) (7)
  
• 关键词：Esophageal cancer ; Neoadjuvant chemoradiation ; Tetrathiomolybdate ; Cisplatin ; Paclitaxel
• 刊名：Investigational New Drugs
• 出版年：2013
• 出版时间：April 2013
• 年：2013
• 卷：31
• 期：2
• 页码：435-442
• 全文大小：390KB
• 参考文献：1. Jemal A, Siegel R, Xu J et al (2010) Cancer statistics. CA Cancer J Clin 60:277鈥?00 class="external" href="http://dx.doi.org/10.3322/caac.20073">CrossRef
  2. Urba SG, Orringer MB, Ianettonni M et al (2003) Concurrent cisplatin, paclitaxel and radiotherapy as preoperative treatment for patients with locoregional esophageal carcinoma. Cancer 98:2177鈥?183 class="external" href="http://dx.doi.org/10.1002/cncr.11759">CrossRef
  3. Gaast AV, van Hagen P, Hulshof M, et al. (2010) Effect of preoperative concurrent chemoradiotherapy on survival of patients with resectable esophageal or esophagogastric junction cancer: Results from a multicenter randomized phase III study. J Clin Oncol 28:15s, (Suppl; abstr 4004)
  4. Sharma R, Yang GY, Nava HR, et al. (2009) A single institution experience with neoadjuvant chemoradiation (CRT) with irinotecan (I) and cisplatin (C) in locally advanced esophageal carcinoma (LAEC), J Clin Oncol 27:15s, (Suppl; abstr 15619)
  5. Brewer GJ, Hedera P, Kluin KJ et al (2003) Treatment of Wilson鈥檚 disease with tetrathiomolybdate III. Initial therapy in a total of 55 neurology affected patients and follow-up with zinc therapy. Arch Neurol 60:378鈥?85 class="external" href="http://dx.doi.org/10.1001/archneur.60.3.379">CrossRef
  6. Brewer GJ, Askari F, Lorincz MT et al (2006) Treatment of Wilson鈥檚 disease with ammonium tetrathiomolybdate: IV. Comparison of tetrathiomolybdate and trientine in a double blind study of treatment of neurologic presentation of Wilson鈥檚 disease. Arch Neurol 63:521鈥?27 class="external" href="http://dx.doi.org/10.1001/archneur.63.4.521">CrossRef
  7. Pan Q, Kleer CG, van Golen KL et al (2002) Copper deficiency induced by tetrathiomolybdate suppresses tumor growth and angiogenesis. Cancer Res 62:4854鈥?859
  8. Pan Q, Bao LW, Merajver SD (2003) Tetrathiomolybdate inhibits angiogenesis and metastasis through suppression of the NF魏B signaling cascade. Mol Canc Res 1:701鈥?06
  9. Brewer GJ, Dick RD, Grover DK et al (2000) Treatment of metastatic cancer with tetrathiomolybdate, and anticopper, antiangiogenic agent: Phase I study. Clin Cancer Res 6:1鈥?0
  10. Henry NL, Dunn R, Merajver S et al (2006) Phase II trial of copper depletion with tetrathiomolybdate as an antiangiogenesis strategy in patients with hormone-refractory prostate cancer. Oncology 71:168鈥?75 class="external" href="http://dx.doi.org/10.1159/000106066">CrossRef
  11. Redman BG, Esper P, Pan Q et al (2003) Phase II trial of tetrathiomolybdate in patients with advanced kidney cancer. Clin Cancer Res 9:1666鈥?672
  12. Gartner EM, Griffith KA, Pan Q et al (2009) A pilot trial of the anti-angiogenic copper lowering agent tetrathiomolybdate in combination with irinotecan, 5-fluorouracil and leucovorin for metastatic colon cancer. Investig New Drugs 27:159鈥?65 class="external" href="http://dx.doi.org/10.1007/s10637-008-9165-9">CrossRef
  13. Brewer GJ (2003) Tetrathiomolybdate anticopper therapy for Wilson鈥檚 disease inhibits angiogenesis, fibrosis and inflammation. J Cell Mol Med 7:11鈥?0 class="external" href="http://dx.doi.org/10.1111/j.1582-4934.2003.tb00198.x">CrossRef
  14. Brewer GJ, Merajver S (1999) Treatment of metastatic cancer with the anticopper, antiangiogenic, tetrathiomolybdate. J Investig Med 47:223A
  15. Cockcroft DW, Gault MH (1976) Prediction of creatinine clearance from serum creatinine. Nephro 16:31鈥?1 class="external" href="http://dx.doi.org/10.1159/000180580">CrossRef
  16. Kaplan EL, Meier P (1958) Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457鈥?81 class="external" href="http://dx.doi.org/10.1080/01621459.1958.10501452">CrossRef
  17. Saltz LB, Clarke S, Diaz-Rubio E et al (2008) Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 26:2013鈥?019 class="external" href="http://dx.doi.org/10.1200/JCO.2007.14.9930">CrossRef
  18. Sandler A, Gray R, Perry MC et al (2007) Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 355:2542鈥?550 class="external" href="http://dx.doi.org/10.1056/NEJMoa061884">CrossRef
  19. Miller K, Wang M, Gralow J et al (2007) Paclitaxel Plus Bevacizumab Versus Paclitaxel Alone for Metastatic Breast Cancer. N Engl J Med 35:2666鈥?676 class="external" href="http://dx.doi.org/10.1056/NEJMoa072113">CrossRef
  20. Hassouneh B, Islam M, Nagel T et al (2007) Tetrathiomolybdate promotes tumor necrosis and prevents distant metastases by suppressing angiogenesis in head and neck cancer. Mol Cancer Ther 6:1039鈥?045 class="external" href="http://dx.doi.org/10.1158/1535-7163.MCT-06-0524">CrossRef
  21. Pass HI, Brewer GJ, Dick R et al (2008) A phase II trial of tetrathiomolybdate after surgery for malignant mesothelioma: final results. Ann Thorac Surg 86:383鈥?90 class="external" href="http://dx.doi.org/10.1016/j.athoracsur.2008.03.016">CrossRef
  22. Cunningham D, Allum WH, Stenning SP et al (2006) Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 355:11鈥?0 class="external" href="http://dx.doi.org/10.1056/NEJMoa055531">CrossRef
  
• 作者单位：Bryan J. Schneider (1)
  Julia Shin-Jung Lee (2) (9)
  James A. Hayman (3)
  Andrew C. Chang (4)
  Mark B. Orringer (4)
  Allan Pickens (5)
  Charlie C. Pan (6)
  Sofia D. Merajver (7) (8)
  Susan G. Urba (10) (7)
  
  1. Division of Hematology/Oncology, Department of Internal Medicine, Weill Cornell Medical College, 1305 York Avenue, 7th floor, New York, NY, 10021, USA
  2. Biostatistics Core Facility, University of Michigan Cancer Center, Ann Arbor, MI, USA
  9. Institute for Social Research Program in Survey Methodology, University of Michigan, Room 4050, 426 Thompson Street, Ann Arbor, MI, 48104-2321, USA
  3. Department of Radiation Oncology, University of Michigan, 1500 E Medical Ctr Dr, SPC 5010, UH B2C490, Ann Arbor, MI, 48109-5010, USA
  4. Department of Thoracic Surgery, University of Michigan, A. Alfred Taubman Health Care Center, 1500 East Medical Center Drive, Room 2120, Ann Arbor, MI, 48109-5344, USA
  5. Department of Thoracic Surgery, Emory University Hospital,, Midtown 550 Peachtree Street, NE Atlanta, GA, 30308, USA
  6. Bellin Health Care System, 1580 Commanche Avenue, Green Bay, WI, 54313, USA
  7. Division of Hematology/Oncology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI, USA
  8. Department of Internal Medicine, University of Michigan Comp Cancer Ctr, 7217 CCGC, 1500 E Medcl Ctr Dr, Ann Arbor, MI, 48109-0948, USA
  10. Department of Internal Medicine, University of Michigan Comp Cancer Ctr, C347 MIB, SPC 5848, 1500 E Medcl Ctr Dr, Ann Arbor, MI, 48109-5848, USA
  
• ISSN：1573-0646

文摘